Roffman Miller Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$27.9M Buy
23,289
+3,240
+16% +$3.31M 1.46% 25
2026
Q1
$18.4M Buy
20,049
+898
+5% +$910K 1.06% 36
2025
Q4
$20.6M Buy
19,151
+2,629
+16% +$2.51M 1.12% 33
2025
Q3
$12.6M Buy
+16,522
New +$12.3M 0.71% 44
2020
Q3
Sell
-4,484
Closed -$736K 112
2020
Q2
$736K Buy
+4,484
New +$688K 0.07% 81

Other funds holding LLY

Roffman Miller Associates's LLY Position: Q2 2026 in Review

Roffman Miller Associates increased its Eli Lilly (LLY) stake by 16% in Q2 2026, buying an estimated $3.31M and bringing the position to 23,289 shares worth $27.9M. The position accounts for 1.46% of the portfolio, ranked #25.

Roffman Miller Associates first reported a position in LLY in Q2 2020 and has held it in 5 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Roffman Miller Associates held 23,289 shares of Eli Lilly worth $27.9M as of Q2 2026.
  • Roffman Miller Associates bought 3,240 Eli Lilly shares in Q2 2026, an estimated $3.31M.
  • Eli Lilly made up 1.46% of Roffman Miller Associates's portfolio in Q2 2026, its #25 holding.
  • Roffman Miller Associates first reported a position in Eli Lilly in Q2 2020 and has held it in 5 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Roffman Miller Associates's 13F filing for Q2 2026, filed 13 Jul 2026.